Recursion Pharmaceuticals, Inc. RXRX Q1 2025 earnings
Reported May 5, 2025 · Before market open
Revenue$14.7MBeat by $785.0K
EPS-$0.50Miss by $0.06
Revenue estimate$14.0M
EPS estimate-$0.44
Next report
Aug 4, 2026 (In 6 days)Revenue estimate$11.0M
EPS estimate-$0.25
Financials
Q1 2025Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
Ask the moment Recursion Pharmaceuticals, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Recursion Pharmaceuticals, Inc. report Q1 2025 earnings?
- Recursion Pharmaceuticals, Inc. (RXRX) reported Q1 2025 earnings on May 5, 2025 before market open.
- What were Recursion Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
- Recursion Pharmaceuticals, Inc. reported revenue of $14.7M and eps of $-0.50 for Q1 2025.
- Did Recursion Pharmaceuticals, Inc. beat estimates in Q1 2025?
- Revenue beat the consensus estimate of $14.0M by $785.0K. EPS missed the consensus estimate of $-0.44 by $0.06.
- How did Recursion Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 6.9% from $13.8M a year earlier and eps declined 28.2% from $-0.39.
- Where can I find Recursion Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
- You can read the 10-Q periodic report (0001601830-25-000075) directly on SEC EDGAR. The filing index links above go to sec.gov.